Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Shareholders for Bristol-Myers Squibb Company, held on May 3, 2022. The filing details the voting outcomes for director elections, executive compensation, auditor ratification, and shareholder proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events rather than a financial statement.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Director Elections: All 10 nominees were elected to serve until the 2023 Annual Meeting. Votes ranged from approximately 1.44 billion to 1.54 billion "For" votes.
- Executive Compensation: The advisory vote to approve the compensation of named executive officers was approved with approximately 1.42 billion "For" votes.
- Auditor Ratification: The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for 2022 was ratified with approximately 1.77 billion "For" votes.
- Shareholder Proposals:
- A proposal to lower the ownership threshold for special shareholder meetings to 10% was not approved (533 million "For" vs. 1.01 billion "Against").
- A proposal to adopt a Board policy requiring an independent Chairperson was not approved (692 million "For" vs. 853 million "Against").
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the reporting of shareholder vote tallies.
Investor Verification Checklist
- Verify the composition of the Board of Directors following the election of the 10 nominees.
- Confirm the ratification of Deloitte & Touche LLP as the independent auditor for the 2022 fiscal year.
- Note the rejection of shareholder proposals regarding the special meeting threshold and independent Board Chair policy.
- Review the "Against" vote counts for specific directors (e.g., Giovanni Caforio, M.D. received ~105 million "Against" votes) to assess shareholder sentiment.